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http://dx.doi.org/10.1016/j.ccell.2015.05.002SUMMARYThe role of the microenvironment in T cell acute lymphoblastic leukemia (T-ALL), or any acute leukemia, is
poorly understood. Here we demonstrate that T-ALL cells are in direct, stable contact with CXCL12-produc-
ing bone marrow stroma. Cxcl12 deletion from vascular endothelial, but not perivascular, cells impeded
tumor growth, suggesting a vascular niche for T-ALL. Moreover, genetic targeting of Cxcr4 in murine
T-ALL after disease onset led to rapid, sustained disease remission, and CXCR4 antagonism suppressed hu-
man T-ALL in primary xenografts. Loss of CXCR4 targeted key T-ALL regulators, including theMYC pathway,
and decreased leukemia initiating cell activity in vivo. Our data identify a T-ALL niche and suggest targeting
CXCL12/CXCR4 signaling as a powerful therapeutic approach for T-ALL.INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common of
childhood cancers, and 15%–20% of ALL cases are T lineage
(T-ALL) (Pui et al., 2011). A quarter of childhood T-ALL patients
relapse within 5 years of treatment and receive a dismal prog-
nosis (Nguyen et al., 2008). Factors predicting poor survival of
relapsed childhood ALL patients include T lineage disease and
isolated bone marrow involvement, both of which have a less
than 25% five-year survival rate (Bhojwani and Pui, 2013;Significance
While much is known about the cell-intrinsic factors that suppo
the microenvironment. T cell acute lymphoblastic leukemia (T
downstream of surface receptors that regulate differentiatio
cues, and it is unknown whether this frees T-ALL from dep
CXCL12-producing vascular endothelial cells as a required com
CXCL12/CXCR4 signaling after disease onset dramatically red
ease, suggesting a powerful therapeutic approach for this devNguyen et al., 2008). Therefore, the search for more effective,
less toxic treatments continues. A series of seminal papers has
demonstrated that themajority of T-ALL cases are driven by acti-
vating NOTCH1 mutations and activation of downstream path-
ways, including MYC signaling, which has been shown to be
essential for T-ALL cell proliferation and leukemia-initiating cell
(LIC) activity (Girard et al., 1996; King et al., 2013; Pear et al.,
1996; Roderick et al., 2014; Weng et al., 2004).
Increasing evidence suggests that leukemic stemcells actively
engage in crosstalk with the bone marrow microenvironment tort leukemia progression, little is understood about the role of
-ALL) cells have commonly acquired mutations in pathways
n, survival, and proliferation in response to environmental
endence on a putative leukemic niche. Here we identify
ponent of a T-ALL niche. Moreover, we show that targeting
uces T-ALL burden in murine and xenograft models of dis-
astating cancer.
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regulate their proliferation and survival (Ayala et al., 2009). Simi-
larities between LICs and hematopoietic stem cells (HSCs) have
raised the hypothesis that LICs require a specialized microenvi-
ronment to survive and that disrupting this niche may be a prom-
ising therapeutic strategy (Scadden, 2014). During the last
decade, cellular components of the HSC niche have been identi-
fiedandanalyzed (MorrisonandScadden, 2014). Imagingstudies
showed that HSCs tend to localize in the proximity of blood ves-
sels, focusing the field’s attention on the perivascular niche (Su-
giyama et al., 2006). In vivo depletion of Nestin+ CXCL12high
mesenchymal stem cells (MSCs) that surround blood vessels re-
sulted in impaired progenitor cell homing andmaintenance (Me´n-
dez-Ferrer et al., 2010). Elegantwork byDingandMorrison (2013)
andGreenbaumet al. (2013) identified endothelial andperivascu-
lar populationsasdistinct andspecializednichessupportingHSC
homeostasis.
Given the functional similarities between HSCs and LICs, such
as the ability to self-renew and suppress differentiation, we hy-
pothesized that they share dependence on common exogenous
signals. In this study, we explore the mechanisms underlying
the interaction of leukemia with its microenvironment and
investigate the role of CXCL12:CXCR4 signaling in T-ALL
pathogenesis.
RESULTS
Visualization of CXCL12-Rich T-ALL Niches in the Bone
Marrow
We hypothesized that CXCL12 produced by the bone marrow
stroma is an important exogenous factor for maintenance of leu-
kemia, analogous to normal HSCs and CLPs (common lympho-
cyte progenitors). To model human T-ALL, we generated T-ALL
driven by mutated human NOTCH1 (Notch1-DE) (Aster et al.,
1997). In this model, Lineagenegc-Kit+ bone marrow progenitor
cells are transduced with a retrovirus encoding Notch1-DE-
IRES-GFP and transplanted into lethally irradiated recipient
mice. The progenitor cells give rise to GFP+ leukemic blasts
with an atypical CD4+CD8+ phenotype in peripheral blood,
bonemarrow, spleen, thymus, lymph nodes, liver, lung, and cen-
tral nervous system. It was previously suggested that leukemic
cells can themselves produce niche factors, augmenting trophic
effects (Colmone and Sipkins, 2008). qRT-PCR analysis of
mouse T-ALL demonstrated that leukemic cells express unde-
tectable levels of Cxcl12 (Figure S1A). As a second test of
whether T-ALL cells can produce CXCL12, we induced T-ALL
by transducing bone marrow stem and progenitor cells from
Cxcl12-DsRed reporter mice or wild-type littermates with
Notch1-DE-GFP retrovirus and transplanted them into irradiated
syngeneic hosts (Ding and Morrison, 2013). T-ALL cells gener-
ated from Cxcl12-DsRed donors did not express detectable
levels of DsRed, indicating that the tumor cells were not able
to produce CXCL12 in an autocrine fashion (Figures S1B–S1D).
To visualize potential interactions of leukemia cells with the
CXCL12-producing microenvironment, GFP+ T-ALL cells iso-
lated from leukemic mice were transplanted into Cxcl12-DsRed
hosts. Analysis of host bone marrow sections revealed organ-
wide dissemination of GFP+ T-ALL cells (Figure 1A), and these
cells were observed to be in direct contact with DsRed+ cells
(Figures 1B and 1C). We then performed time-lapse intravital im-756 Cancer Cell 27, 755–768, June 8, 2015 ª2015 Elsevier Inc.aging of an intact tibia in vivo. Mice were anesthetized, and the
medial or soleus region of the tibial bone was surgically exposed
and imaged. Imaging in live animals showed dissemination of
leukemic cells throughout the bone marrow (Figure 1D; Movie
S1). High-resolution analysis showed leukemic cells to be
directly interacting with CXCL12-producing stroma (Figures
1E–1G). Time-lapse analysis of Cxcl12-DsRed hosts injected
concomitantly with GFP+ T-ALL cells and CFP+ normal CD4+
T cells revealed a dynamic microenvironment, where leukemic
cells were highly immotile and stably associated with stromal
cells in sharp contrast to motile CD4+ T cells (Figures 1F, 1H,
and 1I; Movie S2). These studies have identified a niche for
T-ALL cells and revealed unique adhesion and motility patterns
of leukemic cells in the bone marrow during the early onset of
disease.
CXCL12 Produced by Vascular Endothelial Cells
Is Necessary for T-ALL Progression
We next tested whether CXCL12 plays an important trophic role
in T-ALL. It was previously demonstrated that in the bone
marrow, CXCL12 is expressed by numerous lineages including
endothelial cells, perivascular cells, and osteoblasts (Figure 2A;
Figures S2Aa and S2Ab) (Ding and Morrison, 2013; Greenbaum
et al., 2013; Sugiyama et al., 2006). To visualize these distinct
niche populations in vivo, lineage-specific Cre-transgenic mice
were crossed to Cre reporter mice, in which tdTomato preceded
by a floxed transcriptional stop is knocked into the Rosa26 locus
(LoxP-tdTomato). Col2.3-cre;LoxP-tdTomato mice were used to
specifically label the endosteal niche by activating tdTomato in
fetal and post-natal osteoblasts. Expression of tdTomato was
seen in cells lining the bone in a pattern typical of osteoblasts
(Figures S2Ac and S2Ad). To label perivascular cells, Lepr-cre
trangenic mice were crossed to LoxP-tdTomato mice (Lepr-cre;
LoxP-tdTomato) (Figures S2Ae and S2Af), as it was previously
demonstrated that Leprin receptor is highly expressed in peri-
vascular stromal cells (Zhou et al., 2014). To visualize the vascu-
lature, VEcad-cre;LoxP-tdTomato mice were used. The pattern
of tdTomato expression induced by VEcad-cre (Figures S2Ag
and S2Ah) was identical to the one observed upon intravenous
injection of a VE-cadherin specific antibody (data not shown).
To investigate whether leukemic cells preferentially localize
with osteoblasts or the vasculature (i.e., bone marrow sinusoids)
early in disease, VEcad-cre;LoxP-tdTomato, Lepr-cre;LoxP-
tdTomato, and Col2.3-cre;LoxP-tdTomato hosts were suble-
thally irradiated and injected with 1 million GFP+ T-ALL cells.
One week later, two-photon imaging analysis showed that
leukemic cells associated with VE-Cad+ and Lepr+ cells, but
not osteoblasts (Figures 2B and 2C). We confirmed these results
using two additional types of T-ALL: ETP (Il7r 241-242TCmutant)
(Treanor et al., 2014) and an N-ethyl-N-nitrosourea (ENU)-
induced mutant carrying G7084 (ins)C7085 in the PEST domain
of Notch1 (Figures S2B and S2C). This was an unexpected
finding, as it was previously shown that Col2.3+ osteoblasts
constitute a niche for lymphoid progenitor cells in the bone
marrow (Ding and Morrison, 2013; Greenbaum et al., 2013).
To assess whether CXCL12 production by vascular endothe-
lial cells or by closely associated perivascular cells regulates
T-ALL progression, we deleted Cxcl12 in these populations by
crossing Cxcl12fl/fl mice to VEcad-cre (vascular) or Lepr-cre
Figure 1. T-ALL Cells Interact with a CXCL12-Producing Niche in the Bone Marrow
(A–C) Three different representative immunofluorescence stainings of femur sections from Cxcl12-DsRed mice transplanted with GFP+ T-ALL cells (n = 4).
(D and E) Two different representative high-resolution two-photon images from Cxcl12-DsRed mice transplanted with GFP+ T-ALL cells.
(F) Representative high-resolution two-photon image from Cxcl12-DsRed mice transplanted with GFP+ T-ALL and CFP+ CD4+ T cells.
(G) Percentage of GFP+ T-ALL cells in contact with Cxcl12-DsRed+ cells. Each data point is taken from a different movie or image.
(H and I) Track velocity (H) and displacement velocity (I) of GFP+ T-ALL cells and CFP+ CD4+ T cells.
Error bars represent ± SD. Unless otherwise stated, each panel reflects data from at least three independent experiments. See also Figure S1 and Movies S1
and S2.(perivascular) mice. We then established secondary T-ALL by
transplanting GFP+ T-ALL cells (106) into sublethally irradiated
VE-Cad-cre;Cxcl12fl/fl, Lepr-cre;Cxcl12fl/fl, or littermate sex-
matched control hosts. Consecutive bleeds to monitor leukemia
progression between day 11 and day 19 after transplantation re-
vealed reduced expansion of T-ALL cells in mice lacking
CXCL12 production specifically within the vascular compart-
ment compared with controls (Figure 2D). Moreover, when the
mice were sacrificed on day 25 after transplantation, we
observed a significant reduction in tumor burden compared
with controls when CXCL12 was absent in vascular cells (Fig-
ure 2E). Consistent with this finding, splenomegaly and thymicinfiltration were not observed in VEcad-cre;Cxcl12fl/fl mice, in
contrast to control animals (Figures 2F and S2D–S2F). Histo-
pathological analysis also showed that T-ALL cells aggressively
infiltrated non-hematopoietic tissues such as liver and lungs in
control hosts, while these tissues were virtually leukemia-free
in VEcad-cre;Cxcl12fl/fl mice (Figure 2G). Meanwhile, leukemia
burden in Lepr-cre;Cxcl12fl/fl hosts was statistically equivalent
to control animals (Figures 2D and 2E). These findings demon-
strate that vascular endothelial cells play a key role in leukemia
progression through production of CXCL12. These findings
contrast with the requirement for both perivascular and endothe-
lial CXCL12 for HSCs in normal hematopoiesis.Cancer Cell 27, 755–768, June 8, 2015 ª2015 Elsevier Inc. 757
Figure 2. CXCL12 Production by Vascular Endothelial Cells Maintains T-ALL
(A) Schematic representation of CXCL12-producing populations in bone marrow.
(B) Two-photon images of bone marrow from Cxcl12-DsRed, VEcad-cre;LoxP-tdTomato, Lepr-cre;LoxP-tdTomato, and Col2.3-cre;LoxP-tdTomato animals
1 week after transfer of GFP+ T-ALL cells.
(C) Frequency of co-localization between GFP+ T-ALL and DsRed/tdTomato niche cells from Cxcl12-DsRed, VEcad-cre;LoxP-tdTomato, Lepr-cre;LoxP-
tdTomato, and Col2.3-cre;LoxP-tdTomato animals 1 week after transfer of leukemic cells. At least three animals were used for each condition. Error bars
represent ± SD.
(D) Representative frequency of T-ALL GFP+ cells in blood 11 days and 19 days after secondary transplantation into VEcad-cre;Cxcl12fl/fl, Lepr-cre;Cxcl12fl/fl, or
control hosts.
(E) Absolute numbers of T-ALL cells in lymph nodes, spleen, and bone marrow 25 days after secondary transplantation of GFP+ T-ALL cells into VEcad-
cre;Cxcl12fl/fl, Lepr-cre;Cxcl12fl/fl, or control hosts. Bone marrow numbers represent cells harvested from tibias and femurs. Data is representative of three
(legend continued on next page)
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Figure 3. CXCR4 Is Highly Expressed on the Surface of Mouse and Human T-ALL Cells
(A) Surface CXCR4 expression on T-ALL cells from a representative leukemic mouse and normal T cells from a healthy control. T-ALL cells were identified as
CD4+CD8+GFP+.
(B) Surface CXCR4 mean fluorescence intensity (MFI) on T-ALL cells and normal T cells from the indicated organs. The graph pools data from 3 to 5 pairs of
leukemic mice and controls. Bars represent mean MFI.
(C) Abundance of Cxcr4 mRNA expressed relative to Hprt mRNA in purified normal CD4+CD8+ thymocytes, normal spleen CD4+ T cells, and CD4+CD8+ T-ALL
cells, measured by qRT-PCR. Bars represent the mean.
(D) Surface CXCR4 expression on human peripheral blood CD4+CD3+ and CD8+CD3+ lymphocytes from healthy controls.
(E) Surface CXCR4 expression on primary bone marrow human biopsies from T-ALL patients expanded in immunodeficient hosts (gated on hCD45) (patients 1–4
and 8; patient 4 had ETP T-ALL) and primary T-ALL bone marrow biopsies (patients 5–7).
See also Figure S3.T-ALL Cells Express High Surface Levels of CXCR4
Given the importance of CXCL12 for T-ALL progression, we pro-
filedmouse T-ALL cells for surface expression of CXCL12 recep-
tors CXCR4 and CXCR7. We found that primary mouse T-ALL
cells express markedly high surface levels of CXCR4, but little
surface CXCR7 (Figures 3A and S3A). When we comparedexperiments for VEcad-cre;Cxcl12fl/fl (n = 6) or littermate sex-matched control ani
(n = 8). Error bars represent ± SD.
(F) Image of representative spleens from VEcad-cre;Cxcl12fl/fl or control animals
(G) Histology of lungs and liver from VEcad-cre;Cxcl12fl/fl or control animals.
See also Figure S2.CXCR4 staining on the surface of primary mouse T-ALL cells in
thymus, spleen, and bone marrow to normal T cells from healthy
mice in the corresponding tissues, we found that the mean fluo-
rescence intensity (MFI) of CXCR4 on T-ALL cells was 10- to
50-fold higher than on mature CD4+ T cells and comparable to
normalCD4+CD8+ (double-positive [DP]) thymocytes (Figure 3B).mals (n = 7) and two experiments for Lepr-cre;Cxcl12fl/fl (n = 9) or control hosts
.
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Notably, this pattern of elevated surface CXCR4 protein expres-
sion was not reflected in the level of Cxcr4mRNA transcripts, as
spleen T-ALL cells expressed only marginally higher levels of
Cxcr4 mRNA than spleen CD4+ T cells and lower levels than
DP thymocytes (Figure 3C).
In agreement with these findings, global microarray analysis of
T-ALL patient cohorts (Zhang et al., 2012) failed to reveal signif-
icant differences in CXCR4 expression when compared with
mature human T cells (Figure S3B). However, when we assessed
CXCR4 surface expression on patient T cell leukemia cells and
healthy control T cells, we found that T-ALL cells expressed
higher levels of CXCR4 than CD4+CD3+ or CD8+CD3+ T cells
from the peripheral blood of healthy controls (Figures 3D and
3E). These studies demonstrate that T-ALL cells express high
levels of CXCR4 (when compared with normal peripheral
T cells) and suggest that these surface protein levels cannot be
explained by mere transcriptional upregulation of Cxcr4 mRNA.
Genetic Targeting of Cxcr4 Leads to Sustained T-ALL
Remission
To test the requirement for CXCR4 in T-ALL progression, we
examined leukemia burden following genetic ablation of Cxcr4
in vivo. Importantly, we used an inducible Cre recombinase to
delete Cxcr4 after disease establishment. Bone marrow progen-
itor cells derived from Cxcr4f/f Mx1-Cre+ mice or littermate con-
trol mice (Cxcr4+/+ Mx1-Cre+ or Cxcr4f/f) were retrovirally trans-
duced with Notch1-DE-IRES-GFP and transplanted into
lethally irradiated wild-type recipients. Once GFP+ cells were de-
tected in peripheral blood (>10% of lymphocytes; day 0 [Fig-
ure S4A]), both groups were treated with poly(I:C) (days 1, 3,
and 5) to induce Cre transcription and Cxcr4 deletion (Ku¨hn
et al., 1995) (Figures 4A and S4B). CXCR4 staining by flow cy-
tometry confirmed that Cxcr4 was deleted in Cxcr4f/f Mx1-Cre+
T-ALL cells (Figure 4B). One month after Cxcr4 deletion, we
observed a 3-log reduction in the total number of T-ALL cells,
representing a loss in all tissues surveyed, including bone
marrow, spleen, blood, lymph nodes, thymus, lung, liver, and
brain (Figures 4C and 4D).
Given the striking reduction in leukemia burden we observed
after Cxcr4 deletion, we sought to determine whether survival
is prolonged in mice with CXCR4-deficient T-ALL. Indeed,
more than 30 weeks after deletion of Cxcr4, 100% (10/10) of
micewithCxcr4f/f Mx1-Cre+ T-ALL cells were alive and appeared
healthy, compared with 0% (11/11) of mice with Cxcr4+/+ Mx1-
Cre+ T-ALL cells (Figure 4E). Only very low numbers of GFP+ cells
could be recovered from spleens and bone marrow of mice with
CXCR4-deficient T-ALL when they were sacrificed on day 215
after treatment with poly(I:C) (Figure S4C). These experiments
reveal the ability of Cxcr4 deletion after disease onset to lead
to remission in T-ALL, and they further suggest that loss of
CXCR4 signaling directly affects T-ALL initiating cell (LIC) func-
tion. We will revisit the role of CXCR4 in T-ALL LICs later in the
manuscript.
Cxcr4 Deletion Affects Leukemic Cell Localization
and Survival
To investigate the effects ofCxcr4 deletion on T-ALL cells, we in-
jected secondary Cxcl12-DsRed recipients with equal numbers
of primary Cxcr4f/f Mx1-Cre+ or Cxcr4f/f GFP+ T-ALL cells.760 Cancer Cell 27, 755–768, June 8, 2015 ª2015 Elsevier Inc.When both cohorts presented 60% ± 10% GFP+ leukemic cells
in the bloodstream (Figures 5A and 5B), animals were injected
with two doses of poly(I:C) 48 hr apart. Both cohorts were sacri-
ficed 48 hr after the second poly(I:C) injection, and the bone
marrow was examined by immunofluorescence analysis. We
found that even at this early time point, tumor cells were severely
depleted from the bone marrow, and the remaining GFP+ cells
(which had some residual surfaceCXCR4expression)were local-
ized in proximity to the CXCL12-expressing cells (Figure 5C).
To examine the localization of CXCR4-deficient T-ALL cells in
relation to vascular cells, which we found to be the key source of
CXCL12, we transplanted VE-Cad-cre LoxP-tdTomato hosts
with GFP+ Cxcr4f/f Mx1-Cre+ or littermate control Cxcr4f/f
T-ALL cells. Once both cohorts presented 60% ± 5% GFP+
leukemic cells in the blood, the animals were treated with
poly(I:C) and analyzed 24–72 hr later. Time-lapse intravital imag-
ing revealed that while GFP+Cxcr4f/f leukemic cells were present
throughout the bone marrow, Cxcr4f/f Mx1-Cre+ cells were
mainly observed within blood vessels (Figure 5D; Movies S3,
S4, S5, and S6). Moreover, poly(I:C)-treated Cxcr4f/f Mx1-Cre+
cells showed significant levels of Annexin V staining in both the
bone marrow and peripheral blood (Figure 5E), as did wild-type
T-ALL cells isolated from the spleen of VEcad-cre;Cxcl12fl/fl
hosts 6 weeks after transplantation (Figure S5). These results
suggested that CXCR4 expression and signaling influences
both leukemic cell localization and survival. They also contrast
effects between T-ALL and normal stem and progenitor cells,
as in the latter populations, loss of CXCL12 leads to cell mobili-
zation and differentiation but has not been reported to induce
apoptotic death.
Small-Molecule CXCR4 Inhibitors Suppress Growth
of Murine and Human T-ALL
Small-molecule CXCR4 antagonists have been developed as a
strategy to disrupt the interaction between CXCR4 and
CXCL12 and have been used in various settings, including
HSC mobilization (Rettig et al., 2012). Therefore, we examined
whether CXCR4 antagonists can recapitulate the effects of
Cxcr4 gene ablation and limit T-ALL expansion. To this end,
we transplanted two cohorts of lethally irradiated mice with
Notch1-DE-IRES-GFP+ bone marrow progenitor cells, and after
>5% peripheral blood lymphocytes constituted GFP+ leukemic
blasts, we administered AMD3465 (20 nmol/hr) or PBS via os-
motic pump. After two weeks of treatment, mice treated with
AMD3465 showed a substantial reduction in leukemia burden
across all tissues surveyed (Figure 6A). These results demon-
strate the significant anti-leukemia activity of CXCR4 antago-
nists, even as single drugs.
To test whether the ability of CXCR4 inhibition to suppress
murine leukemia translates to human disease, we assessed
the effect of AMD3465 on human xenografts, obtained from
primary human bone marrow biopsies (corresponding to pa-
tient 1 and patient 2 in Figure 3E). We first expanded the pri-
mary human leukemia cells in immune-deficient NOD/
MrkBomTac-Prkdcscid (NOD-SCID) hosts for 6 weeks. Subse-
quently, two million human T-ALL cells were transplanted
into secondary NOD-SCID hosts and peripheral blood was
monitored for the appearance of human CD45+ (hCD45+)
leukemic cells. Once leukemia constituted >5% of white blood
Figure 4. Deletion of Cxcr4 Reduces T-ALL Burden and Significantly Prolongs Survival
(A) Schematic representation of experiment design.
(B) Representative surface CXCR4 staining on Cxcr4f/f Mx1-Cre+ or littermate control (Cxcr4+/+Mx1-Cre+or Cxcr4f/f) GFP+ T-ALL cells in the spleen 1 month after
they were treated with poly(I:C).
(C) Number of GFP+ Cxcr4f/f Mx1-Cre+ or littermate control (Cxcr4+/+Mx1-Cre+or Cxcr4f/f) T-ALL cells in the indicated tissues 1 month after treatment with
poly(I:C) (initiated after GFP+ cells represented >10%of peripheral blood lymphocytes). Bars represent themean. Data are pooled from two experiments (n = 7–8).
(D) Representative immunofluorescence staining of a femur section from a mouse that received Cxcr4f/f Mx1-Cre+ or littermate control T-ALL, 1 month after
poly(I:C) treatment.
(E) Kaplan-Meier survival graph of mice with Cxcr4f/f Mx1-Cre+ (n = 10) or littermate control (Cxcr4+/+ Mx1-Cre+, n = 11) T-ALL following poly(I:C) treatment
(initiated after T-ALL cells reached 10% of blood lymphocytes; first poly(I:C) injection was defined as day 1).
See also Figure S4.cells in blood, we began treatment with AMD3465 or vehicle
using osmotic pumps. Two weeks later, animals were sacri-
ficed and the leukemia burden was assessed. As a result of
AMD3465 treatment, the number of hCD45+ cells in bloodand spleen was significantly reduced (Figures 6B–6D). Further-
more, splenomegaly was substantially decreased in xeno-
grafted mice treated with AMD3465 compared with vehicle
(PBS) (Figures 6E and S6). Histo-pathological analysis showedCancer Cell 27, 755–768, June 8, 2015 ª2015 Elsevier Inc. 761
Figure 5. Effects of CXCR4 Depletion on Leukemic Cell Localization and Survival
(A) Schematic representation of experiment design.
(B) Left: frequency of transplanted Cxcr4f/f Mx1-Cre+ or littermate control T-ALL GFP+ cells in the blood prior to poly(I:C) treatment. Right: frequency of GFP+
leukemic cells and levels of CXCR4 in the bone marrow 48 hr after the second dose of poly(I:C).
(C) Representative immunofluorescence staining of a femur section from Cxcl12-DsRed hosts transplanted with GFP+ Cxcr4f/f Mx1-Cre+ or littermate control
T-ALL cells 48 hr after poly(I:C) treatment.
(D) Top: experiment design. Bottom: representative high-resolution two-photon image from VEcad-cre;LoxP-tdTomatomice transplantedwithCxcr4f/f Mx1-Cre+
or littermate control T-ALL 24 hr after poly(I:C) treatment. Arrows indicate a presence or absence of leukemic cells on top of the vessels.
(E) Annexin V staining on GFP+ Cxcr4f/f Mx1-Cre+ or littermate control T-ALL cells in blood and bone marrow 24 hr after poly(I:C) treatment (n = 3).
See also Figure S5 and Movies S3, S4, S5, and S6.that T-ALL cells in PBS-treated hosts aggressively infiltrated
non-hematopoietic tissues, such as brain, liver, and lungs.
The same tissues in the AMD3465-treated cohort were virtually762 Cancer Cell 27, 755–768, June 8, 2015 ª2015 Elsevier Inc.leukemia-free, highlighting the ability of AMD3465 to control
primary human T-ALL progression in a xenograft model (Fig-
ure 6F). These results provide the basis for further testing of
this small-molecule inhibitor in the clinical setting as a targeted
T-ALL therapy.
CXCR4 Controls a T-ALL-Specific Gene Expression
Program and Modulates Leukemia-Initiating Activity
in T-ALL
To assess the consequences of CXCR4 signaling loss on T-ALL
gene transcription, high-throughput transcriptome sequencing
(RNA sequencing [RNA-seq]) was performed on splenic Cxcr4f/f
Mx1-Cre+ and Cxcr4f/f control T-ALL cells 10 days after poly(I:C)
treatment to induce Cxcr4 deletion. RNA-seq was also per-
formed on primary splenic T-ALL cells co-cultured with OP9 cells
(which produce CXCL12 [Janas et al., 2010; Trampont et al.,
2010]) in the presence of the CXCR4 antagonist AMD3100 or
vehicle for 4 days (Figures 7A–7C, S7A, and S7B). Initial analysis
of theCxcr4-targeted data revealed changes in genes significant
for early T cell development and T-ALL induction and progres-
sion such as Cdk4, Notch3, Il2ra (CD25), Ptcra, and Cdkn2a.
Although altered expression of some of these genes could ac-
count for the T-ALL phenotype (i.e., Ptcra expression promotes
T-ALL progression), gene set enrichment analysis (GSEA) also
demonstrated a significant enrichment of genes that are down-
regulated in response to Cxcr4 deletion or AMD3100 treatment
in vitro in Myc DNA binding databases (Figures 7C and S7B)
(Kim et al., 2008; King et al., 2013; Schuhmacher et al., 2001).
Consistent with this, we observed reduced Myc protein levels
in T-ALL cells purified after Cxcr4 ablation with poly(I:C) (Fig-
ure S7C); after treatment of wild-type T-ALL cells with
AMD3465 in vivo (Figure S7D); and in wild-type T-ALL cells iso-
lated from VEcad-cre;Cxcl12fl/fl mice (Figure S7E), which also
demonstrated reduced Myc and Myc target gene expression
(Figure S7F). Myc overexpression partially restored the prolifera-
tion of primary mouse T-ALL cells cultured in the presence of
AMD3465, suggesting Myc is an important factor downstream
of CXCR4 in T-ALL cells (Figure S7G).
We have previously shown that T-ALL LICs are characterized
by high levels of Myc protein. Furthermore, Myc deletion or
silencing in established disease specifically targets LICs and
leads to disease remission (King et al., 2013; Roderick et al.,
2014). We observed reduced Myc protein expression following
AMD3465 treatment of mouse LICs expressing a MYC-GFP
fusion allele, cultured in vitro (Figure 7D) (King et al., 2013). To
assess the role of CXCR4 signaling in LIC function in vivo, we
compared the ability of CXCR4-deficient and wild-type primary
T-ALL cells to establish secondary leukemia upon transfer into
irradiated recipients. Mice with Cxcr4f/f Mx1-Cre+ or control
Cxcr4+/+ Mx1-Cre+ primary T-ALL were treated with three doses
of poly(I:C), and 3 days after the final dose, T-ALL cells were iso-
lated from spleen and bone marrow and transferred into suble-
thally irradiated wild-type mice (1 million per mouse, for each
genotype). Ten weeks after transplantation, recipients of
poly(I:C)-treated control T-ALL cells displayed severe spleno-
megaly and lymphadenopathy (Figure 7E), and fluorescence-
activated cell sorting (FACS) analysis revealed that the cells
had multiplied by more than three orders of magnitude in each
of the tissues surveyed (Figure 7F). In contrast, recipients of
poly(I:C)-treated Cxcr4f/f Mx1-Cre+ T-ALL cells appeared
healthy, with very few or no leukemia cells detected in the
same array of tissues. Our data support a critical role forCXCR4 in regulating T-ALL LIC activity, in agreement with our
findings showing prolonged survival (Figure 4E) upon deletion
of Cxcr4 in established T-ALL and our transcriptome profiling
that connected loss of Cxcr4 expression to decreased levels of
Myc protein.
DISCUSSION
The importance of CXCR4 in T-ALL pathogenesis would not
have been anticipated on the basis of its role in normal T cell
maturation. T cell development is profoundly dependent, at
different stages, on signaling through Notch1, pre- T cell recep-
tor (TCR)/TCR, and interleukin-7 receptor (IL-7R) (Ciofani and
Zu´n˜iga-Pflu¨cker, 2007; Di Santo and Rodewald, 1998; Radtke
et al., 1999). All three receptors and components of their
signaling pathways have been implicated in T-ALL initiation
and progression. By contrast, while CXCR4 signaling increases
the efficiency of normal T cell development, CXCR4 is not essen-
tial for T cell maturation (Ara et al., 2003; Janas et al., 2010; Tram-
pont et al., 2010). However, our studies demonstrated an
essential role for CXCR4 signaling in the progression of T-ALL,
suggesting distinct requirements for CXCL12/CXCR4 signaling
between physiology and disease.
The efficacy of CXCR4 inhibition would also not have been
anticipated on the basis of the precedent of other hematological
malignancies, in which CXCR4 inhibition has been promising but
has not had as dramatic effects as a single agent as the ones
shown here, including rapid induction of leukemia cell death
(Beider et al., 2014; Chen et al., 2013; Kuhne et al., 2013; Tavor
et al., 2004; Uy et al., 2012; Welschinger et al., 2013; Zeng
et al., 2009). CXCR4 retains normal developing B and myeloid
cells in the bone marrow. B and myeloid leukemia cells appear
to share this dependence onCXCR4, as CXCR4 antagonismmo-
bilizes these cells out of the bone marrow and into the blood-
stream, depriving them of stromal support and exposing them
to co-administered chemotherapeutic drugs. Loss of CXCR4
signaling may also inhibit metastasis and predispose these cells
to apoptosis (Burger and Peled, 2009). Hence it is surprising that
T-ALL appears to be more susceptible to CXCR4 antagonism
than B andmyeloid cancers; we hypothesize that this may reflect
a different dependence of LICs on CXCR4. Finally, although in
other tumors (i.e., AML) CXCR4 surface expression is variable,
most likely reflecting the heterogeneity of the disease (Mo¨hle
et al., 1998), our data suggest that CXCR4 expression on T-ALL
is more uniform. Indeed, we have observed high surface
CXCR4 on all T-ALL subtypes, including early T precursor
(ETP-ALL), a more immature and high-risk disease subtype
(Treanor et al., 2014; Zhang et al., 2012). However, we cannot
exclude at this point that there are no mechanisms of resistance
to CXCR4 signaling inhibition, as T-ALL can be initiated by a
large spectrum of mutations, some of them altering signaling
pathways (i.e., KRAS, PTEN, JAK3) or epigenetic regulators
(i.e., UTX, EZH2, PHF6). It is thus conceivable that inactivation
by some of these genes could lead to disease refractory to
CXCR4 inhibition.
All these suggest that targeting the CXCL12-expressing
microenvironment might have significant implications for the
treatment of pediatric and adult T-ALL. Interestingly, recent clin-
ical trial data using AMD3100 (Plerixafor) demonstrated that theCancer Cell 27, 755–768, June 8, 2015 ª2015 Elsevier Inc. 763
(legend on next page)
764 Cancer Cell 27, 755–768, June 8, 2015 ª2015 Elsevier Inc.
drug is absorbed quickly and is well tolerated (McDermott et al.,
2014; Uy et al., 2012). It has orphan drug status for the mobiliza-
tion of HSCs and was approved by the U.S. Food and Drug
Administration for this indication. While safety needs to be
further validated in T-ALL patients and especially children af-
flicted by the disease, our results in murine and xenograft
models, together with the results reported in a companion paper
in this issue ofCancer Cell (Passaro et al., 2015), provide a strong
foundation for the assessment of CXCR4 antagonists in clinical
trials, either as a single agent or more likely in combination
with established chemotherapy regimens. They also suggest
the power of therapeutic targeting of the cancer microenviron-
ment in leukemia.
EXPERIMENTAL PROCEDURES
Animals
Female C57BL/6mice (6–8 weeks old) were obtained from the National Cancer
Institute. Nonobese diabetic/severe combined immunodeficient NOD/
MrkBomTac-Prkdcscid (NOD-SCID) mice were from Taconic. Mx1-Cre (Ku¨hn
et al., 1995), VEcad-Cre (B6.FVB-Tg(Cdh5-cre)7Mlia/J) (Alva et al., 2006),
Lepr-cre (B6.129-Leprtm2(cre)Rck/J) (DeFalco et al., 2001), Col2.3-cre
(B6.Cg-Tg(Col1a1-cre/ERT2)1Crm/J) (Kim et al., 2004), andRosa26-tdTomato
(B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J) (Madisen et al., 2010) mice
were from Jackson Laboratory.Cxcr4f/f (Nie et al., 2004),Cxcl12DsRed knock-in
(Ding and Morrison, 2013), MycGFP(Huang et al., 2008), and Fbxw7 knock-in
mutant mice (King et al., 2013) have previously been described. To induce
deletion by Mx1-Cre, mice received three intraperitoneal injections of poly(I:C)
(10 ug/g, GE Heathcare) in PBS, administered every other day. Mice were
housed in specific pathogen-free conditions at the Skirball Institute animal fa-
cility. All animal experiments were performed in accordance with protocols
approved by the New York University Institutional Animal Care and Use
Committee.
Bone Marrow Transduction and Transplantation
Hematopoietic stem and progenitor cells were enriched from bone marrow
by magnetic selection of cells expressing c-kit (STEMCELL) and were
cultured in the presence of 50 ng/mL Flt3 ligand, 50 ng/mL stem cell factor
(SCF), 10 ng/mL interleukin-7 (IL-7), and 10 ng/mL interleukin-6 (IL-6)
(PeproTech). 24 and 48 hr after enrichment, c-kit+ cells were infected
with concentrated retrovirus. Transduction efficiency was determined by re-
porter fluorescence at 96 hr. For induction of primary T-ALL, irradiated
mice (two rounds of 550 rads) received 50,000 Notch1-DE-IRES-GFP+ lin-
eage cells, together with 500,000 unfractionated bone marrow cells for
hemogenic support, by retro-orbital injection. For secondary T-ALL trans-
plantation, recipients were sublethally irradiated (400 rads) and retro-orbi-
tally injected with 1–2 3 106 Notch1-DE-GFP+ cells from spleen or bone
marrow. For niche experiments all the recipient hosts were sex-matched
littermates.Figure 6. Small-Molecule CXCR4 Antagonists Efficiently Suppress Gro
(A) T-ALL was induced by transfer of Notch1-DE-GFP transduced progenitors. Af
with AMD3465 (20 nmol/hr) or vehicle (PBS) were implanted subcutaneously (s
treatment initiation. Bars represent the mean.
(B–F) NOD-SCID mice were injected with leukemia cells from patient 1 or 2 (repre
pumps filled with AMD3465 (25 nmol/hr) or vehicle were implanted s.c. Analysis
(B) Representative flow cytometric analysis of human CD45 (hCD45) expression a
hCD45+ cells ± SEM.
(C and D) Number of hCD45+ leukemia cells per milliliter of peripheral blood (C) or i
mean.
(E) Image of representative spleens and lymph nodes (patient 1 xenograft).
(F) Histology of lungs, liver, and brain (patient 1 xenograft).
Data for (B)–(F) are representative of six to seven mice per group using cells derive
See also Figure S6.Establishment of Xenografted Human T-ALL
For human xenograft studies, NOD-SCID host mice were used. Primary T-ALL
patient samples were collected by Columbia Presbyterian Hospital with
informed consent and approved and analyzed under the supervision of the
Columbia University Medical Center Institutional Review Board. 1–53 106 pa-
tient cells were transplanted into immunodeficient mouse strains via retro-
orbital injection. Cells from spleen of these primary recipients were used for
experiments.
In Vivo Animal Treatments
For inhibition of CXCR4 in primary mouse T-ALL, mice were anaesthetized by
isoflurane inhalation and implanted subcutaneously with osmotic pumps
(model 2002; Alzet) filled with 40 mM AMD3465 (in PBS; Tocris) or PBS (flow
rate 0.5 ul/hr). Acute CXCR4 inhibition was achieved with two subcutaneous
injections of 25 mg/kg AMD3465 (or PBS control) given 4 hr apart. For
CXCR4 inhibition in xenografted patient T-ALL, NOD-SCID mice were im-
planted with osmotic pumps filled with 50 mM AMD3465 or PBS. Mice im-
planted with osmotic pumps were sacrificed 14 days later for analysis of tumor
burden by flow cytometry.
Cell Culture and In Vitro Drug Treatments
Primary mouse T-ALL cells isolated from spleen were maintained on OP9 stro-
mal cells in OptiMEM + GlutaMAX (Invitrogen) supplemented with 10% fetal
bovine serum (FBS), 5 ng/ml IL-7, penicillin and streptomycin, and 55 mM
b-mercaptoethanol and passaged every 3–4 days onto a fresh feeder layer.
OP9 cells were pre-treated with 7.5 ng/mL mitomycin C (Sigma) to prevent
feeder cell division. Mouse ETP T-ALL (Treanor et al., 2014) and a T-ALL cell
line generated by ENUmutagenesis carrying a Notch1 PEST domain mutation
(G7084 (ins)C7085; generated in the lab of A.F., Columbia University) were
maintained on OP9-DLL4 feeders. AMD3100 octahydrochloride hydrate
(10 ug/mL in water; Sigma), AMD3465 hexahydrobromide (50 ug/mL in water;
Tocris or Cayman Chemical), or vehicle were added to culture media at the
start of the culture period.
RNA Extraction and Library Construction for Next Generation
Sequencing
Total RNA was extracted from samples using RNeasy Plus Mini Kit (Life Tech-
nologies). Samples were then subject to PolyA selection using oligo-dT beads
(Life Technologies) according to the manufacturer’s instructions. The resulting
RNA samples were then used as input for library construction using the deoxy-
UTP (dUTP) method as described (Parkhomchuk et al., 2009). RNA libraries
were then sequenced on the Illumina HiSeq 2000 or 2500 using 50-bp sin-
gle-end reads. All RNA-seq data were aligned to mm9 using TopHat v1.4
(Trapnell et al., 2009) with default parameters. We used Cuffdiff v1.3 (Trapnell
et al., 2010) for all differential expression (DE) analyses with the RefSeq anno-
tation. In all DE tests, a gene was considered significant if the q value was less
than 0.05 (Cuffdiff default).
Two-Photon Preparation Imaging
Mice were anesthetized using isoflurane and secured on a warming imaging
plate in a supine position. The medial or soleus region of the tibial bone waswth of Murine and Human T-ALL
ter GFP+ leukemic cells reached 5% of white blood cells, osmotic pumps filled
.c.). Graphs show T-ALL cell number in the indicated tissues 2 weeks after
sented in Figure 3E). After leukemia reached 5% of white blood cells, osmotic
was 2 weeks after treatment initiation.
mong peripheral blood lymphocytes. Values represent the mean frequency of
n the spleen (D) of animals treated with AMD3465 or vehicle. Bars represent the
d from patient 1 or five to six mice per group using cells derived from patient 2.
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Figure 7. CXCR4 Regulates a T Cell-Specific Gene Signature and Promotes LIC Activity in T-ALL
(A) Heatmap displaying differentially expressed genes in Cxcr4f/f and Cxcr4f/f Mx1-Cre T-ALL cells 10 days after administration of poly(I:C).
(B) Scatter plot comparing log2-transformed FPKM expression values for CXCR4-wild-type and -deficient T-ALL cells. Each dot represents an individual gene.
Red dots represent genes of interest overexpressed in CXCR4-wild-type (y axis) compared with CXCR4-deficient T-ALL cells (x axis).
(C) Myc expression signatures are enriched in T-ALL cells with intact CXCR4 signaling as determined by GSEA. Top: comparison ofCxcr4f/f andCxcr4f/f Mx1-Cre
T-ALL cells. Bottom: comparison of T-ALL cells treated with AMD3100 or vehicle for 4 days in vitro.
(D) MYC-GFP expression by Fbxw7mut Notch1-DE LICs expressing aMYC-GFP fusion allele, 4 days after culture on OP9 cells in media with AMD3465 or vehicle,
measured by flow cytometry. The graph represents three experiments.
(E and F) Cxcr4f/f Mx1-Cre or control Cxcr4+/+ Mx1-Cre Notch1-DE+ T-ALL cells treated with poly(I:C) in vivo were isolated from spleen and bone marrow and
transferred into sublethally irradiated wild-type mice (1 million cells per mouse; n = 3 recipients per genotype). (E) Image shows spleens and lymph nodes
harvested from secondary recipients 10 weeks after transplantation. (F) Cell number of Cxcr4+/+ Mx1-Cre or Cxcr4f/f Mx1-Cre T-ALL cells in indicated tissues of
secondary recipients 10 weeks after transplantation, assessed by flow cytometry. Bars represent the mean.
See also Figure S7.surgically exposed removing soft tissue. The bone was carefully thinned to
approximately 200 mm thickness using a microdrill. The leg was imbedded in
agarose to stabilize the area and create an immersion well for the microscope
objective. Images were collected on an Olympus FV-1000MPE upright laser
scanning microscope with a 253 1.05 NA water immersion objective using a
Spectra-physics DeepSee-MaiTai Ti:sapphire pulsed laser for excitation,
with emission filters for the detection of GFP and rhodamine (Tomato or DsRed766 Cancer Cell 27, 755–768, June 8, 2015 ª2015 Elsevier Inc.fluorescent proteins) and qdot 705 (Invitrogen). Images were analyzed on Vo-
locity 6.3 (Improvision). Analysis of cell co-localization is included in Supple-
mental Experimental Procedures.
Statistical Analysis
Statistical analysis (excluding RNA-seq experiments) was conducted using the
PRISM program (GraphPad). Two groups were compared using an unpaired
t test or the Mann-Whitney test. More than two groups were compared
using the Kruskal-Wallis test. Significance was defined as *p < 0.05, **p <
0.01, *** p < 0.001, ****p < 0.0001.
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The accession number for the RNA-seq data reported in this paper is NCBI
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seven figures, and six movies and can be found with this article online at
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